IDEAYA Posts $125.7 Million Third-Quarter Loss, Says Cash Runway Extends to 2030
Key Facts
IDEAYA Biosciences said on November 3, 2026, that it posted a net loss of $125.7 million for the three months ended September 30, compared with a loss of $112.5 million in the second quarter ended June 30. Basic and diluted loss per share was $1.22, compared with $0.34 in the third quarter of 2025, according to the company. The quarterly loss widened alongside higher research and development expenses, which the company said mainly reflected increased clinical trial, development and personnel costs. Management said its expectation that liquidity would extend into 2030 remained unchanged under its current operating plan. The results put clinical spending and available liquidity at the center of the quarter's picture, alongside progress in the company's metastatic uveal melanoma program.
Collaboration revenue was $10.2 million in the third quarter, up from $8.9 million in the second quarter, according to IDEAYA's statement. The revenue is tied to research and development services the company provides under its exclusive licensing agreement with Servier for darovasertib. The company recognizes revenue as those services are performed, and the remaining balance of its research and development service obligations was $139.8 million on September 30. Investing.com reported an estimate of $6.98 million in quarterly revenue, against actual revenue of $10.24 million, and said revenue exceeded estimates. The website also reported an estimated loss per share of $1.17, compared with the reported loss of $1.22, meaning the loss per share was worse than the average forecast cited in its report.
Research and development expenses rose to $121.6 million in the third quarter from $108.7 million in the second quarter, according to the company statement published via PR Newswire. IDEAYA attributed the increase mainly to higher clinical trial, development and personnel-related costs. This coincided with a higher quarterly net loss as the company focused on advancing its clinical programs and providing research and development services under the Servier agreement. CEO Yujiro Hata said the quarter saw “completion of the submission of the first NDA for darovasertib to treat metastatic uveal melanoma.” He added that the company looked forward to presenting new preclinical data from its portfolio in RAS-mutant cancers. These developments link higher expenses with the oncology drug development path outlined by the company in its business update.
During the third quarter, IDEAYA submitted an NDA to the U.S. Food and Drug Administration in support of potential approval of darovasertib with crizotinib for metastatic uveal melanoma. The company said data from two ongoing trials in this cancer were presented at the 2026 European Society for Medical Oncology Congress in Madrid. It said the results support the potential of the combination across disease cases regardless of HLA-A*02:01 status or line of therapy. The regulatory submission followed the presentation of those clinical data, while the company continues to advance the program alongside its other programs. In its update, management listed completion of the first NDA submission among the quarter's key achievements, without specifying a date for a regulatory decision on the application.
IDEAYA had about $1.15 billion in cash, cash equivalents and marketable securities on September 30, compared with $1.24 billion on June 30. The company said the decline was mainly due to net cash used in operations. Despite the lower balance during the quarter, management maintained its guidance that liquidity would extend into 2030, based on its current operating plan. The outlook comes amid a quarterly net loss of $125.7 million and research and development expenses of $121.6 million. The cash balance and expected runway through 2030 provide financial context for the company's announced research and clinical pipeline, according to management's estimate.
For its clinical portfolio, IDEAYA expected to report initial clinical data from its global Phase 1/2 trial of IDE849 by the end of 2026 or early 2027. The company update gave no more precise timing than that window. It also announced an R&D Day in London on November 16, 2026, to present preclinical data on strategies targeting KRAS-mutant cancers. The announced topics include combining MTAP/CDKN2A deletion targeting with RAS inhibitors. The company said the presentation would cover its precision medicine portfolio and opportunities to target MTAP/CDKN2A deletion, while the CEO linked the event to the presentation of new data from its RAS-mutant cancer programs.
IDYA shares closed at $31.64 on November 2, 2026, according to EL7 data. That was the day before the company announced its third-quarter results and business update. The available data here do not include a documented trading range for the stock during the November 2 session. The figures also do not include the stock's movement after the results announcement on November 3. The company-set milestones following the announcement are initial IDE849 data expected by the end of 2026 or early 2027, and the R&D Day scheduled for November 16.